Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Change in Inventory: 2010-2025

Historic Change in Inventory for Lifecore Biomedical (LFCR) over the last 14 years, with May 2025 value amounting to -$2.3 million.

  • Lifecore Biomedical's Change in Inventory fell 845.63% to -$2.3 million in Q2 2025 from the same period last year, while for May 2025 it was -$7.7 million, marking a year-over-year decrease of 791.88%. This contributed to the annual value of -$7.7 million for FY2025, which is 791.88% down from last year.
  • Lifecore Biomedical's Change in Inventory amounted to -$2.3 million in Q2 2025, which was up 50.12% from -$4.6 million recorded in Q1 2025.
  • Lifecore Biomedical's Change in Inventory's 5-year high stood at $12.2 million during Q4 2022, with a 5-year trough of -$8.2 million in Q2 2022.
  • Over the past 3 years, Lifecore Biomedical's median Change in Inventory value was -$140,000 (recorded in 2023), while the average stood at -$331,500.
  • Examining YoY changes over the last 5 years, Lifecore Biomedical's Change in Inventory showed a top increase of 958.33% in 2024 and a maximum decrease of 895.08% in 2024.
  • Over the past 5 years, Lifecore Biomedical's Change in Inventory (Quarterly) stood at $9.5 million in 2021, then increased by 27.44% to $12.2 million in 2022, then slumped by 102.01% to -$244,000 in 2023, then slumped by 895.08% to -$2.4 million in 2024, then tumbled by 845.63% to -$2.3 million in 2025.
  • Its Change in Inventory stands at -$2.3 million for Q2 2025, versus -$4.6 million for Q1 2025 and -$2.4 million for Q4 2024.